Ashu Tyagi is Director at Y-mAbs Therapeutics, Inc. (YMAB). They have made 1 open-market trade across 1 company since 2018, most recently 2025-09-16.
CIK 0001752467
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $6.9M since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| YMAB | 30,905 | $266K |
Shares reported on the most recent Form 4, priced at the 2025-07-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| YMAB | BUY | 2018-09-25 | 2018-09-26 | $16.00 | $6.9M | -3.8% | -9.7% | -31.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.